Portfolio Manager Charles Hamieh joins Matt Bushby for a discussion of how the team analyses the return profiles of infrastructure companies across the globe, from user-pays assets such as rails and airports to regulated utilities.
To learn more about the ClearBridge Global Infrastructure Income Strategy, click the button below.
Explore the Global Infrastructure Income Strategy
Drug development appears to be stabilizing, as improving biopharma funding and healthier demand create a more constructive backdrop for contract research organizations and life science tools companies.
Read full article